Radar plots: A novel modality for displaying disparate data on the efficacy of eluxadoline for the treatment of irritable bowel syndrome with diarrhea
dc.contributor.author | Brenner, D. M. | |
dc.contributor.author | Dove, L. S. | |
dc.contributor.author | Andrae, D. A. | |
dc.contributor.author | Covington, P. S. | |
dc.contributor.author | Gutman, C. | |
dc.contributor.author | Chey, W. D. | |
dc.date.accessioned | 2018-08-13T18:49:47Z | |
dc.date.available | 2019-10-01T16:02:10Z | en |
dc.date.issued | 2018-08 | |
dc.identifier.citation | Brenner, D. M.; Dove, L. S.; Andrae, D. A.; Covington, P. S.; Gutman, C.; Chey, W. D. (2018). "Radar plots: A novel modality for displaying disparate data on the efficacy of eluxadoline for the treatment of irritable bowel syndrome with diarrhea." Neurogastroenterology & Motility 30(8): n/a-n/a. | |
dc.identifier.issn | 1350-1925 | |
dc.identifier.issn | 1365-2982 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/145265 | |
dc.description.abstract | BackgroundPatients with irritable bowel syndrome with diarrhea (IBS‐D) experience a range of abdominal and bowel symptoms; successful management requires alleviation of this constellation of symptoms. Eluxadoline, a locally active mixed μ‐ and κ‐opioid receptor agonist and δ‐opioid receptor antagonist, is approved for the treatment of IBS‐D in adults based on the results of 2 Phase 3 studies. Radar plots can facilitate comprehensive, visual evaluation of diverse but interrelated efficacy endpoints.MethodsTwo double‐blind, placebo‐controlled, Phase 3 trials (IBS‐3001 and IBS‐3002) randomized patients meeting Rome III criteria for IBS‐D to twice‐daily eluxadoline 75 or 100 mg or placebo. Radar plots were prepared showing pooled Weeks 1‐26 response rates for the primary efficacy composite endpoint (simultaneous improvement in abdominal pain and stool consistency), stool consistency, abdominal pain, urgency‐free days, and adequate relief, and change from baseline to Week 26 in IBS‐D global symptom score, abdominal discomfort, abdominal pain, abdominal bloating, and daily number of bowel movements.Key ResultsThe studies enrolled 2428 patients. Eluxadoline increased Weeks 1‐26 responder proportions vs placebo for the composite endpoint, stool consistency, abdominal pain, urgency‐free days, and adequate relief. Changes from baseline to Week 26 in IBS‐D global symptom score, abdominal discomfort, abdominal pain, abdominal bloating, and number of bowel movements were greater with eluxadoline vs placebo.Conclusions and InferencesData presentation in radar plot format facilitates interpretation across multiple domains, demonstrating that eluxadoline treatment led to improvements vs placebo across 13 endpoints representing the range of symptoms experienced by patients with IBS‐D.Data presentation in radar plot format can facilitate evaluation of the diverse array of symptoms and outcomes that are relevant to a symptom‐based condition like irritable bowel syndrome with diarrhea (IBS‐D). In 2 Phase 3 trials, eluxadoline treatment improved stool consistency and frequency, abdominal pain, bloating and discomfort, feelings of urgency, global symptom score, and adequate relief. Radar plots provide a visual demonstration of improvements with eluxadoline across 13 endpoints encompassing the diverse constellation of symptoms experienced by patients with IBS‐D. | |
dc.publisher | American Psychiatric Press Ltd | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | abdominal pain | |
dc.subject.other | eluxadoline | |
dc.subject.other | diarrhea | |
dc.subject.other | radar plots | |
dc.subject.other | irritable bowel syndrome | |
dc.title | Radar plots: A novel modality for displaying disparate data on the efficacy of eluxadoline for the treatment of irritable bowel syndrome with diarrhea | |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/145265/1/nmo13331_am.pdf | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/145265/2/nmo13331.pdf | |
dc.identifier.doi | 10.1111/nmo.13331 | |
dc.identifier.source | Neurogastroenterology & Motility | |
dc.identifier.citedreference | Strand V, Loftis JE. Response to M. Boers’ concerns about spydergrams. J Clin Epidemiol. 2013; 66: 247 ‐ 252. | |
dc.identifier.citedreference | Ikechi R, Fischer BD, DeSipio J, Phadtare S. Irritable bowel syndrome: clinical manifestations, dietary influences, and management. Healthcare (Basel). 2017; 5: 21. | |
dc.identifier.citedreference | Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology. 2016; 150: 1393 ‐ 1407. | |
dc.identifier.citedreference | Lucak S, Chang L, Halpert A, Harris LA. Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence‐based treatment in practice. Therap Adv Gastroenterol. 2017; 10: 253 ‐ 275. | |
dc.identifier.citedreference | Atarodi S, Rafieian S, Whorwell PJ. Faecal incontinence‐the hidden scourge of irritable bowel syndrome: a cross‐sectional study. BMJ Open Gastroenterol. 2014; 1: e000002. | |
dc.identifier.citedreference | American Gastroenterological Association. IBS in America: Survey Summary Findings. http://ibsinamerica.gastro.org/files/IBS_in_America_Survey_Report_2015-12-16.pdf. Accessed October 5, 2016. | |
dc.identifier.citedreference | Drossman DA, Morris CB, Schneck S, et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol. 2009; 43: 541 ‐ 550. | |
dc.identifier.citedreference | Spiegel B, Strickland A, Naliboff BD, Mayer EA, Chang L. Predictors of patient‐assessed illness severity in irritable bowel syndrome. Am J Gastroenterol. 2008; 103: 2536 ‐ 2543. | |
dc.identifier.citedreference | Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014; 109 ( Suppl 1 ): S2 ‐ S26. | |
dc.identifier.citedreference | Buono JL, Mathur K, Averitt AJ, Andrae DA. Economic burden of inadequate symptom control among US commercially insured patients with irritable bowel syndrome with diarrhea. J Med Econ. 2017; 20: 353 ‐ 362. | |
dc.identifier.citedreference | Buono JL, Mathur K, Averitt A, Andrae DA. Economic burden of irritable bowel syndrome with diarrhea: retrospective analysis of a U.S. commercially insured population. J Manag Care Spec Pharm. 2017; 23: 453 ‐ 460. | |
dc.identifier.citedreference | US Food and Drug Administration. Viberzi. Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/206940s002lbl.pdf. Accessed June 19, 2017. | |
dc.identifier.citedreference | Lembo AJ, Lacy BE, Zuckerman MJ, et al. Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J Med. 2016; 374: 242 ‐ 253. | |
dc.identifier.citedreference | Chey WD, Dove LS, Andrae DA, Covington PS. Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies. Aliment Pharmacol Ther. 2017; 45: 1319 ‐ 1328. | |
dc.identifier.citedreference | Saary MJ. Radar plots: a useful way for presenting multivariate health care data. J Clin Epidemiol. 2008; 61: 311 ‐ 317. | |
dc.identifier.citedreference | De Vincentis A, Pennazza G, Santonico M, et al. Breath‐print analysis by e‐nose for classifying and monitoring chronic liver disease: a proof‐of‐concept study. Sci Rep. 2016; 6: 25337. | |
dc.identifier.citedreference | Exeter DJ, Zhao J, Hanham G, Grey C, Wells S, Kerr A. Construction and use of mapping techniques to describe the geographical distribution of medication dispensing for the secondary prevention of atherosclerotic CVD in New Zealand: VIEW‐2. N Z Med J. 2014; 127: 70 ‐ 80. | |
dc.identifier.citedreference | Ford CE, Malley D, Bateman A, Clare IC, Wagner AP, Gracey F. Selection and visualisation of outcome measures for complex post‐acute acquired brain injury rehabilitation interventions. NeuroRehabilitation. 2016; 39: 65 ‐ 79. | |
dc.identifier.citedreference | Yamaguchi N, Matsubara S, Momonoi F, Morikawa K, Takeyama M, Maeda Y. An attempt of radar chart expression of a self‐rating scale for sleep disturbance. Psychiatry Clin Neurosci. 1998; 52: 165 ‐ 167. | |
dc.identifier.citedreference | Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997; 32: 920 ‐ 924. | |
dc.identifier.citedreference | Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006; 130: 1480 ‐ 1491. | |
dc.identifier.citedreference | American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐5), 5th edn. Washington, DC: American Psychiatric Press Ltd; 2013. | |
dc.identifier.citedreference | US Department of Health and Human Services. NIAAA Newsletter. Winter 2004, Number 3. http://www.niaaa.nih.gov/sites/default/files/newsletters/Newsletter_Number3.pdf. Accessed June 19, 2017. | |
dc.identifier.citedreference | Chang L, Lembo A, Sultan S. American Gastroenterological Association Institute technical review on the pharmacological management of irritable bowel syndrome. Gastroenterology. 2014; 147: 1149 ‐ 1172. | |
dc.identifier.citedreference | Trinkley KE, Nahata MC. Medication management of irritable bowel syndrome. Digestion. 2014; 89: 253 ‐ 267. | |
dc.identifier.citedreference | Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014; 6: 71 ‐ 80. | |
dc.identifier.citedreference | Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta‐analysis. Clin Gastroenterol Hepatol. 2012; 10: 712 ‐ 721. | |
dc.identifier.citedreference | Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015; 313: 949 ‐ 958. | |
dc.identifier.citedreference | Drossman DA, Hasler WL. Rome IV‐functional GI disorders: disorders of gut‐brain interaction. Gastroenterology. 2016; 150: 1257 ‐ 1261. | |
dc.identifier.citedreference | Schmulson MJ, Drossman DA. What is new in Rome IV. J Neurogastroenterol Motil. 2017; 23: 151 ‐ 163. | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.